Eton Pharmaceuticals (NASDAQ:ETON) Shares Up 5.1% – Still a Buy?

Posted by Geri Gentry on Oct 16th, 2026

Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) shares traded up 5.1% during trading on Wednesday. The stock traded as high as $55.96 and last traded at $56.0510. Approximately 52,455 shares were traded during trading, a decline of 88% from the average session volume of 447,982 shares. The stock had previously closed at $53.33.

Wall Street Analysts Forecast Growth

ETON has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Canaccord Genuity Group upped their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a report on Friday, August 14th. Craig Hallum reaffirmed a “buy” rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a research report on Thursday. Finally, Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Eton Pharmaceuticals has a consensus rating of “Buy” and an average target price of $71.50.

Get Our Latest Research Report on Eton Pharmaceuticals

Eton Pharmaceuticals Trading Down 2.9%

The company has a market cap of $1.47 billion, a P/E ratio of 135.08 and a beta of 0.90. The stock’s 50-day moving average is $56.38 and its two-hundred day moving average is $41.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The company had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. As a group, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 4,166 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the transaction, the insider directly owned 43,381 shares in the company, valued at approximately $2,388,991.67. This trade represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 79,166 shares of company stock valued at $4,809,672 over the last 90 days. 16.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ETON. EcoR1 Capital LLC lifted its position in Eton Pharmaceuticals by 7.0% during the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after purchasing an additional 141,394 shares in the last quarter. BlackRock Inc. purchased a new stake in Eton Pharmaceuticals in the second quarter worth about $68,629,000. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the second quarter worth about $42,569,426. Pillsbury Lake Capital LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth about $14,015,083. Finally, Panoramic Capital LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth about $7,537,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.